SOCRA - Society of Clinical Research Associates Adverse Event Safety Reporting Questions and Answers 1 — Questions and Answers
Question 1: A subject in a clinical trial for a new hypertension drug experiences a severe headache, is hospitalized overnight for observation, and is discharged the next day with a diagnosis of a migraine. The event resolves. How should the site staff classify this event?
- A non-serious Adverse Event because it resolved completely.
- A Serious Adverse Event (SAE) because it resulted in inpatient hospitalization. (Correct answer)
- Not an Adverse Event because it was diagnosed as a common migraine.
- An unexpected adverse event that does not require expedited reporting.
Correct answer: A Serious Adverse Event (SAE) because it resulted in inpatient hospitalization.
According to the definitions in 21 CFR 312.32 and ICH GCP, an adverse event is considered 'serious' if it results in any of several outcomes, including inpatient hospitalization. The reason for the hospitalization and the final diagnosis do not change its classification as an SAE.
Question 2: According to 21 CFR 312.32, what is the maximum timeframe within which a sponsor must report an unexpected fatal or life-threatening suspected adverse reaction to the FDA?
- 15 calendar days after the sponsor's initial receipt of the information.
- 10 working days after the site reports the event to the sponsor.
- 24 hours after becoming aware of the event.
- 7 calendar days after the sponsor's initial receipt of the information. (Correct answer)
Correct answer: 7 calendar days after the sponsor's initial receipt of the information.
21 CFR 312.32(c)(2) mandates that sponsors must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but no later than 7 calendar days after first receiving the information. The 15-day timeframe applies to serious and unexpected suspected adverse reactions that are not fatal or life-threatening.
Question 3: Which of the following is a primary responsibility of the Principal Investigator regarding adverse event management?
- To document all adverse events and report them to the sponsor according to the protocol-specified timelines and procedures. (Correct answer)
- To report all Serious Adverse Events (SAEs) directly to the FDA within 24 hours.
- To report only unexpected and related adverse events to the Institutional Review Board (IRB).
- To determine the final causality of an event independently of the sponsor's medical monitor.
Correct answer: To document all adverse events and report them to the sponsor according to the protocol-specified timelines and procedures.
The Principal Investigator is responsible for ensuring all adverse events (AEs) are properly documented in the source records and reported to the sponsor. The specific timelines and methods for reporting both serious and non-serious AEs are dictated by the clinical trial protocol. Investigators report SAEs to the sponsor, not directly to the FDA.
Question 4: A subject in a trial for an investigational antidepressant reports developing a mild rash two weeks after starting the drug. The subject has a known history of seasonal allergies and recently started using a new laundry detergent. In assessing this adverse event, what is the MOST critical determination the investigator must make for safety reporting purposes?
- Whether the event meets the criteria for 'serious.'
- The exact date the new laundry detergent was first used.
- If the event needs to be reported to the FDA via MedWatch by the site.
- The likelihood that the event is related to the investigational product (causality). (Correct answer)
Correct answer: The likelihood that the event is related to the investigational product (causality).
The investigator's assessment of causality (i.e., whether there is a reasonable possibility that the drug caused the event) is critical. This determination transforms an 'adverse event' into a 'suspected adverse reaction', which is the basis for expedited safety reporting by the sponsor to the FDA. While seriousness is also important, causality is the key factor that links the event to the drug for regulatory reporting.
Question 5: A sponsor is required by 21 CFR 312.32 to submit an IND safety report to the FDA and all participating investigators for which type of event?
- Any Serious Adverse Event (SAE) that occurs at any study site, regardless of causality.
- A suspected adverse reaction that is both serious and unexpected. (Correct answer)
- Any adverse event that leads to a participant's withdrawal from the study.
- Only for adverse events that are both fatal and definitively related to the investigational drug.
Correct answer: A suspected adverse reaction that is both serious and unexpected.
According to 21 CFR 312.32(c)(1), the sponsor must notify the FDA and all participating investigators of any suspected adverse reaction that is both serious and unexpected. This ensures all investigators are promptly informed of potential new risks, which may affect subject safety or require changes to the protocol or informed consent form.
Question 6: In the context of clinical trial safety reporting, which of the following best defines an 'unexpected' adverse reaction?
- A serious adverse event that occurs with a greater frequency than previously reported.
- An adverse event that is not listed in the clinical trial protocol as a potential risk.
- An adverse reaction, the nature or severity of which is not consistent with the applicable product information, such as the Investigator's Brochure. (Correct answer)
- Any adverse reaction that results in a subject requiring an unscheduled hospital visit.
Correct answer: An adverse reaction, the nature or severity of which is not consistent with the applicable product information, such as the Investigator's Brochure.
The standard regulatory definition from both ICH E2A and 21 CFR 312.32(a) defines an 'unexpected' adverse reaction as one where the nature or severity is not consistent with the current product information, which for an investigational product is the Investigator's Brochure.
SOCRA - Society of Clinical Research Associates Adverse Event Safety Reporting Questions and Answers 1
A subject in a clinical trial for a new hypertension drug experiences a severe headache, is hospitalized overnight for observation, and is discharged the next day with a diagnosis of a migraine.
The event resolves.
How should the site staff classify this event?